Alpha Tau Medical Ltd. (NASDAQ:DRTS - Get Free Report) was the recipient of a significant increase in short interest during the month of January. As of January 15th, there was short interest totalling 72,600 shares, an increase of 7.1% from the December 31st total of 67,800 shares. Based on an average trading volume of 45,600 shares, the days-to-cover ratio is currently 1.6 days. Currently, 0.1% of the shares of the company are short sold.
Institutional Investors Weigh In On Alpha Tau Medical
A hedge fund recently raised its stake in Alpha Tau Medical stock. Levin Capital Strategies L.P. grew its holdings in Alpha Tau Medical Ltd. (NASDAQ:DRTS - Free Report) by 2.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 314,514 shares of the company's stock after purchasing an additional 7,189 shares during the period. Levin Capital Strategies L.P. owned approximately 0.45% of Alpha Tau Medical worth $975,000 at the end of the most recent quarter. Institutional investors and hedge funds own 2.65% of the company's stock.
Alpha Tau Medical Price Performance
Shares of NASDAQ DRTS traded down $0.08 during trading on Friday, reaching $3.15. 94,616 shares of the stock traded hands, compared to its average volume of 145,427. The stock has a market capitalization of $220.25 million, a P/E ratio of -7.33 and a beta of 0.83. Alpha Tau Medical has a 52-week low of $1.75 and a 52-week high of $4.39. The company has a 50-day moving average of $3.37 and a 200-day moving average of $2.65.
Analysts Set New Price Targets
Separately, HC Wainwright restated a "buy" rating and set a $9.00 price target on shares of Alpha Tau Medical in a research note on Friday, November 22nd.
Get Our Latest Stock Report on DRTS
About Alpha Tau Medical
(
Get Free Report)
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.
Recommended Stories
Before you consider Alpha Tau Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alpha Tau Medical wasn't on the list.
While Alpha Tau Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
